Clinical Trials
17
Active:0
Completed:4
Trial Phases
4 Phases
Early Phase 1:1
Phase 2:1
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 4
6 (60.0%)Phase 3
2 (20.0%)Early Phase 1
1 (10.0%)Phase 2
1 (10.0%)An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06613373
Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer
Not yet recruiting
- Conditions
- HER2+ Breast Cancer
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06537674
Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer
Not yet recruiting
- Conditions
- Colorectal CancerColorectal Adenoma
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 50000
- Registration Number
- NCT06136026
Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
Phase 3
Recruiting
- Conditions
- Colon Cancer
- Interventions
- Drug: XLJDOD compound granuleDrug: placebo (XLJDOD mimetic agent)
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 730
- Registration Number
- NCT05709249
- Locations
- 🇨🇳
Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China
Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine
Completed
- Conditions
- Angina Pectoris
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Jiangsu Famous Medical Technology Co., Ltd.
- Target Recruit Count
- 2000
- Registration Number
- NCT05482009
- Locations
- 🇨🇳
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found